These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 39391997)

  • 1. Combined nephrotoxicity of Polymyxins and Vancomycin: a study on adverse event reporting for monotherapy versus combinations using the FDA adverse event reporting system (FAERS).
    Zhan R; Lin J; Dai M; Ji B; He X; Jiang Z
    Expert Opin Drug Saf; 2024 Oct; ():1-6. PubMed ID: 39391997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacovigilance study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.
    Wu T; Shi Y; Xu C; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
    Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38676603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS).
    Truong CB; Durham SH; Qian J
    Expert Opin Drug Saf; 2021 May; 20(5):603-609. PubMed ID: 33573405
    [No Abstract]   [Full Text] [Related]  

  • 4. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
    Phe K; Lee Y; McDaneld PM; Prasad N; Yin T; Figueroa DA; Musick WL; Cottreau JM; Hu M; Tam VH
    Antimicrob Agents Chemother; 2014 May; 58(5):2740-6. PubMed ID: 24566187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
    Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
    Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury.
    Sisay M; Hagos B; Edessa D; Tadiwos Y; Mekuria AN
    Pharmacol Res; 2021 Jan; 163():105328. PubMed ID: 33276108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins.
    Wagenlehner F; Lucenteforte E; Pea F; Soriano A; Tavoschi L; Steele VR; Henriksen AS; Longshaw C; Manissero D; Pecini R; Pogue JM
    Clin Microbiol Infect; 2021 Jan; ():. PubMed ID: 33359542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
    Patek TM; Teng C; Kennedy KE; Alvarez CA; Frei CR
    Drug Saf; 2020 Jan; 43(1):17-22. PubMed ID: 31691256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence.
    Falagas ME; Kyriakidou M; Voulgaris GL; Vokos F; Politi S; Kechagias KS
    J Glob Antimicrob Resist; 2021 Mar; 24():342-359. PubMed ID: 33486122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin.
    Ballı FN; Ekinci PB; Kurtaran M; Kara E; Dizman GT; Sönmezer MÇ; Hayran M; Demirkan K; Metan G
    Int J Antimicrob Agents; 2024 Feb; 63(2):107035. PubMed ID: 37979889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymyxin B vs. colistin: the comparison of neurotoxic and nephrotoxic effects of the two polymyxins.
    Aysert-Yildiz P; Özgen-Top Ö; Şentürk AF; Kanik S; Özger HS; Dizbay M
    BMC Infect Dis; 2024 Aug; 24(1):862. PubMed ID: 39187812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymyxin Monotherapy vs. Combination Therapy for the Treatment of Multidrug-resistant Infections: A Systematic Review and Meta-analysis.
    Samal S; Samir SB; Patra SK; Rath A; Dash A; Nayak B; Mohanty D
    Indian J Crit Care Med; 2021 Feb; 25(2):199-206. PubMed ID: 33707900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study.
    Yang QJ; Xiang BX; Song MH; Yang CY; Liang JH; Xie YL; Zuo XC
    Pharmacotherapy; 2024 Aug; 44(8):631-641. PubMed ID: 39046197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies.
    Oliota AF; Penteado ST; Tonin FS; Fernandez-Llimos F; Sanches AC
    Diagn Microbiol Infect Dis; 2019 May; 94(1):41-49. PubMed ID: 30635223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study.
    Aggarwal R; Dewan A
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):15. PubMed ID: 29571295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vonoprazan-associated
    Ouyang M; Zou S; Cheng Q; Shi X; Zhao Y; Sun M
    Ther Adv Drug Saf; 2024; 15():20420986241260211. PubMed ID: 39091466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.